JPH0774158B2 - 3 species symbiotic mixture - Google Patents
3 species symbiotic mixtureInfo
- Publication number
- JPH0774158B2 JPH0774158B2 JP61206018A JP20601886A JPH0774158B2 JP H0774158 B2 JPH0774158 B2 JP H0774158B2 JP 61206018 A JP61206018 A JP 61206018A JP 20601886 A JP20601886 A JP 20601886A JP H0774158 B2 JPH0774158 B2 JP H0774158B2
- Authority
- JP
- Japan
- Prior art keywords
- bacteria
- symbiotic
- acid bacteria
- lactic acid
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Fodder In General (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
【発明の詳細な説明】 本発明は、活性生菌類の共生混合物に関する。更に詳し
く述べれば、ヒトもしくは動物にとって有益なる乳酸
菌、糖化菌および酪酸菌を有効成分とし、これに適宜賦
形剤を配合して成る３種菌共生混合物に関する。The present invention relates to a symbiotic mixture of active viable fungi. More specifically, the present invention relates to a symbiotic mixture of three kinds of bacteria, which comprises lactic acid bacteria, saccharifying bacteria and butyric acid bacteria, which are beneficial to humans or animals, as active ingredients and which is appropriately mixed with excipients.
活性生菌類は応用微生物工業の各分野において重要な役
割を演じており、これら活性生菌類を２種もしくは２種
以上混合（共存）させた状態で利用（経口投与）する場
合には生体内において微生物の共生現象すなわち共存す
る微生物が互いに有利な影響を与え合うという効果が期
待されることがあるが、この共生現象を積極的に応用し
た製品は少ない。Active live fungi play an important role in each field of the applied microbial industry. In the case of using (orally administering) two or more kinds of these active live fungi in a state of coexistence (oral administration), in vivo The symbiotic phenomenon of microorganisms, that is, the effect that coexisting microorganisms mutually affect each other may be expected, but few products positively apply this symbiotic phenomenon.
本発明者は、共生現象を示す活性生菌共生混合物の応用
に早くから着目し検討を加えた結果、乳酸菌、糖化菌お
よび酪酸菌を有効成分とする３種菌共生混合物を創製
し、医薬品、健康食品、飼料などの分野における製品主
原料への応用に成功した。The present inventor has focused on the application of an active probiotic symbiotic mixture exhibiting a symbiotic phenomenon from an early stage and made a study. We have succeeded in applying it to the main raw materials of products in the fields such as feed.
３種菌共生混合物の各成分間における共生現象に基ずく
菌数の発育増加傾向に関しては以下の通りである。ま
ず、糖化菌と乳酸菌との共生について述べると、乳酸菌
単独培養の場合と糖化菌培養液を添加した培地で乳酸
菌を培養した場合とを比較した時、乳酸菌の菌数におい
て前者の場合に比較して後者の場合には約50〜100倍の
増加傾向が認められる。これは糖化菌が発育時に産生す
るプロテアーゼおよびアミラーゼが周囲（培地あるいは
生体内）の蛋白質および炭水化物をそれぞれ分解して乳
酸菌増殖に必要なアミノ酸（グルタミン酸、アスパラギ
ン酸など）およびブドウ糖を供給し、乳酸菌の発育増殖
を促進させることによるものと考えられる。更に、乳酸
菌と酪酸菌との共生について述べると、それぞれの菌を
単独培養した場合と両菌を混合培養した場合とを比較し
た時、酪酸菌の菌数においては混合培養の方が約10倍前
後、乳酸菌の菌数についても混合培養の方が数倍の増加
傾向が認められる。これは混合培養によってそれぞれの
菌が互いに相手にとって有利な増殖促進因子を産生して
いることによるものと考えられる。The growth tendency of the number of bacteria based on the symbiotic phenomenon among the components of the three-kind symbiotic mixture is as follows. First, to describe the symbiosis of saccharifying bacteria and lactic acid bacteria, when comparing the case of lactic acid bacterium single culture and the case of culturing lactic acid bacteria in a medium containing a saccharifying bacterium culture solution, the number of lactic acid bacteria was compared to the former case. In the latter case, an increasing tendency of about 50 to 100 times is recognized. This is because proteases and amylases produced by saccharifying bacteria during development decompose the surrounding proteins (medium or in vivo) and carbohydrates to supply amino acids (glutamic acid, aspartic acid, etc.) necessary for lactic acid bacteria growth and glucose, It is considered to be due to promotion of growth and proliferation. Furthermore, when describing the symbiosis of lactic acid bacteria and butyric acid bacteria, when comparing the case where each of the bacteria was cultured alone and the case where both bacteria were mixed, the mixed culture had about 10 times the number of butyric acid bacteria. Before and after the mixed culturing, the number of lactic acid bacteria tended to increase several times. This is considered to be due to the fact that the mixed cultures cause the respective bacteria to produce growth-promoting factors that are advantageous to each other.
本発明に適用し得る菌は、乳酸菌としてはストレプトコ
ッカスフェカーリス（Streptococcus faecalis），スト
レプトコッカスラクティス（Streptococcus lactis），
ストレプトコッカスフェシウム（Strptococcus faeciu
m）の他ラクトバチルス（Lactobacillus）属の各菌など
が、糖化菌としてはバチルスメセンテリカス（Bacillus
mesentericus），バチルスズブチルス（Bacillus subt
ilis），バチルスナットー（Bacillus natto）などが、
また酪酸菌としてはクロストリジウムブチリカム（Clos
tridium butyricum），クロストリジウムアセトブチリ
カム（Clostridium acetobutylicum）などがあげられ
る。なお、賦形物質としては、バレイショデンプン，ト
ウモロコシデンプン，乳糖，白糖もしくはこれらの混合
物が適当である。Bacteria applicable to the present invention include, as lactic acid bacteria, Streptococcus faecalis, Streptococcus lactis,
Streptococcus faeciu
m) and other bacteria belonging to the genus Lactobacillus are known as saccharifying bacteria, such as Bacillus mesentericus.
mesentericus), Bacillus subtilus (Bacillus subt)
ilis), Bacillus natto, etc.
Clostridium butyricum (Clos
tridium butyricum), Clostridium acetobutylicum and the like. As the excipient, potato starch, corn starch, lactose, sucrose or a mixture thereof is suitable.
３種の活性生菌の混合割合については、乳酸菌１部に対
し糖化菌および酪酸菌をそれぞれ１部ないし８部程度の
割合にて混合できる。実験データによれば乳酸菌１部に
対して糖化菌4.5〜５部，酪酸菌5.0〜5.5部の混合割合
の場合が菌数増加傾向において効率的である。また、糖
化菌および酪酸菌については芽胞を形成させてから使用
すると耐熱性，耐乾性，耐薬品性が増強される。Regarding the mixing ratio of the three types of active bacteria, 1 part of lactic acid bacteria and 1 part to 8 parts of saccharifying bacteria and butyric acid bacteria can be mixed. According to the experimental data, the ratio of 4.5 to 5 parts of saccharifying bacteria and 5.0 to 5.5 parts of butyric acid bacteria to 1 part of lactic acid bacteria is effective in increasing the number of bacteria. In addition, saccharifying bacteria and butyric acid bacteria, when used after forming spores, have enhanced heat resistance, drought resistance and chemical resistance.
実施例 本発明品を整腸剤（医薬品）へ応用する場合について述
べる。Example The case of applying the product of the present invention to an intestinal rectifying agent (medicine) will be described.
（イ） 使用した活性生菌の菌種 乳酸菌としてストレプトコッカスフェカーリス （Streptococcus faecalis T−110）微工研菌寄第8936
号 糖化菌としてバチルスメセンテリカス （Bacillus mesentericus TO−Ａ）微工研菌寄第8934号 酪酸菌としてクロストリジウムブチリカム （Clostridium butyricum TO−Ａ）微工研菌寄第8935号 （ロ） 各活性生菌および賦形剤の混合割合 乳酸菌原末 １部 糖化菌（芽胞）原末 ５部 酪酸菌（芽胞）原末 ５部 乳 糖 40部 バレイショデンプン 49部 （ハ） 上記のごとく製造した３種菌共生混合物を整腸
剤として使用した。この整腸剤をヒトもしくは動物に経
口投与した際の腸内菌叢への薬理作用は以下の通りであ
る。(B) Species of active live bacteria used Streptococcus faecalis T-110 as a lactic acid bacterium
As saccharifying bacterium, Bacillus mesentericus TO-A No. 8934, as a butyric acid bacterium Clostridium butyricum TO-A Mixture ratio of bacteria and excipients Lactobacillus bulk powder 1 part Saccharifying bacterium (spore) bulk powder 5 parts Butyric acid bacteria (spore) bulk powder 5 parts Lactose 40 parts Potato starch 49 parts (c) Symbiotic bacteria produced as described above The mixture was used as an antiflatulent. The pharmacological action on the intestinal flora when the intestinal stabilizer is orally administered to humans or animals is as follows.
（投与例１） ラットに整腸剤を投与した場合の腸内菌叢の変化を、投
与群と対照群に分けて見たところ、投与群においてビフ
ィズス菌の増加と大腸菌の減少が顕著に確認された。(Administration Example 1) When the changes in the intestinal flora when an antiflatulent was administered to rats were divided into the administration group and the control group, an increase in bifidobacteria and a decrease in Escherichia coli were remarkably confirmed in the administration group. .
（投与例２） ラットに整腸剤を投与し腸管内pHの変動を投与群と対照
群に分けて見たところ、投与群において腸管内pHが有意
に低下した。これにより整腸剤が有害菌の発育を抑制す
ることが考えられる。(Administration Example 2) When an intestinal regulating agent was administered to rats and changes in intestinal pH were divided into the administration group and the control group, the intestinal pH was significantly decreased in the administration group. Therefore, it is considered that the antiflatulent suppresses the growth of harmful bacteria.
（投与例３） 人工乳栄養児に整腸剤を約２週間投与して糞便中におけ
るビフィズス菌の消長を見たところ、ビフィズス菌の有
意な増加が認められた。(Administration Example 3) When the intestinal-regulating agent was administered to an artificial infant for about 2 weeks and the prevalence of bifidobacteria in feces was observed, a significant increase in bifidobacteria was observed.
（投与例４） 急性腸炎並びに習慣性便秘の症例に整腸剤１日量3gを１
日〜７日間投与したところ、有効な成績を得るととも
に、抗生物質投与時に本剤を併用することにより菌交代
症の発生防止が推定された。(Administration Example 4) 1 g of the intestinal preparation daily for the case of acute enteritis and habitual constipation
It was presumed that effective administration was obtained after administration for 1 to 7 days, and that the use of this drug in combination with antibiotics prevented the occurrence of bacterial symptomosis.
上述のごとく、本発明に係る３種菌共生混合物を主原料
として医薬品，健康食品，飼料等に応用する時、経口投
与後体内特に腸管内において各活性生菌が互いに共生現
象を発現し、腸内細菌叢の維持，回復にとって良好なる
使用効果が期待される。As described above, when the three-kind symbiotic mixture according to the present invention is used as a main raw material for medicines, health foods, feeds, etc., each active viable bacterium develops a symbiotic phenomenon with each other in the body, especially in the intestinal tract, after oral administration. Good use effect is expected for maintenance and recovery of bacterial flora.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 ＦＩ 技術表示箇所 Ｃ１２Ｒ 1:145 1:46） ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Office reference number FI technical display location C12R 1: 145 1:46)
Claims (1)
菌、糖化菌および酪酸菌を有効成分とし、これに適宜賦
形剤を配合して成る３種菌共生混合物。1. A symbiotic mixture of three kinds of bacteria, which comprises lactic acid bacteria, saccharifying bacteria and butyric acid bacteria, which are beneficial to humans or animals, as active ingredients, and which is appropriately mixed with excipients.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61206018A JPH0774158B2 (en) | 1986-09-03 | 1986-09-03 | 3 species symbiotic mixture |
| US07/616,820 US5143845A (en) | 1986-09-03 | 1990-11-16 | Mixture of saccarifying lactic acid producing and butyric acid producing bacteria |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61206018A JPH0774158B2 (en) | 1986-09-03 | 1986-09-03 | 3 species symbiotic mixture |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6363620A JPS6363620A (en) | 1988-03-22 |
| JPH0774158B2 true JPH0774158B2 (en) | 1995-08-09 |
Family
ID=16516540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61206018A Expired - Lifetime JPH0774158B2 (en) | 1986-09-03 | 1986-09-03 | 3 species symbiotic mixture |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0774158B2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0367552A (en) * | 1989-05-24 | 1991-03-22 | Toyo Jozo Co Ltd | Stable spore-forming variable cell drug, production thereof and pellet |
| US5292523A (en) * | 1991-12-11 | 1994-03-08 | Nippon Kayaku Kabushiki Kaisha | Method for growth promotion of animals and powder compositions containing killed microbial cells of bacteria belonging to genus clostridium |
| IT1254210B (en) * | 1992-02-10 | 1995-09-14 | Simone Claudio De | DIETARY AND / OR PHARMACEUTICAL COMPOSITIONS BASED ON LYOPHILIZED LACTIC BACTERIA, THEIR PREPARATION AND USE |
| KR20010008211A (en) * | 2000-11-15 | 2001-02-05 | 박준봉 | Functional fermented feed using microorganism producing organic acid and photosynthetic microorganism |
| JP2016193894A (en) * | 2015-04-01 | 2016-11-17 | 京都薬品工業株式会社 | Viable cell-containing preparation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6163618A (en) * | 1984-09-03 | 1986-04-01 | Akira Yamauchi | Cathartic |
-
1986
- 1986-09-03 JP JP61206018A patent/JPH0774158B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6363620A (en) | 1988-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goldin | Health benefits of probiotics | |
| EP0416892B2 (en) | Agents for the prevention and treatment of diarrhoea | |
| US4710379A (en) | Intestinal microflora-improving agent | |
| Hayakawa et al. | Effects of soybean oligosaccharides on human faecal flora | |
| EP0555618B1 (en) | Dietetic and/or pharmaceutical compositions containing lyophilized lactic bacteria | |
| JP2002523372A (en) | Symbiotic lactic acid producing bacteria and uses thereof | |
| JPH10330274A (en) | How to administer live birds | |
| US5143845A (en) | Mixture of saccarifying lactic acid producing and butyric acid producing bacteria | |
| JP2009542204A (en) | Functional lactic acid bacteria fermentation composition excellent in diet effect | |
| JP3648233B2 (en) | Feed composition | |
| GB2076424A (en) | Bifidobacterium-containing confectionery tablets and process for preparing the same | |
| JPH01221319A (en) | Composition for promoting enteral colonization -of useful bacteria and method therefor | |
| JPH0774158B2 (en) | 3 species symbiotic mixture | |
| JP4498924B2 (en) | Lactobacillus casei subspecies casei growth promoting composition | |
| CN1640279A (en) | Active leben slice and its production method | |
| JP7072151B2 (en) | Gut microbiota improver | |
| CN111035661A (en) | Application of lactobacillus plantarum | |
| Ouwehand et al. | Production of probiotic bifidobacteria | |
| JP3587536B2 (en) | Calcium reinforcing agent and method for producing the same | |
| JPWO2020158737A1 (en) | A probiotic composition imparting storage stability and gastric fluid decomposition resistance stability. | |
| WO2020017390A1 (en) | Lactic acid bacterium, natural immune activating agent derived from lactic acid bacterium, and preventive/therapeutic drug for infection and food or beverage | |
| JP2000093166A (en) | Egg white-derived bifidobacterium growth promoting substance and food containing the substance | |
| JP2506314B2 (en) | Prophylactic / therapeutic agent and feed for sepsis in poultry and pigs | |
| RU2173159C2 (en) | Method of production of biologically active food addition | |
| JPH0859492A (en) | Antidiabetic |